Answers are grounded in this paper and cite their sources.
We read with great interest the Nadig et al editorial1Nadig TR, Symth R, Bade B. Counterpoint: liquid markers for risk stratification of pulmonary nodules, ready for prime time? Not yet!Google Scholar highlighting the arguments against the clinical usage of liquid biomarkers for risk stratification of pulmonary nodules. We share their desire for large, prospective randomized controlled trial data to help guide our critical assessment of novel biomarkers and to provide the best care possible to patients with indeterminate pulmonary nodules by diagnosing lung cancer in a timely fashion while avoiding exposure to unnecessary and potentially harmful procedures. Our colleagues suggest that because definitive evidence of clinical utility is not currently available and physicians are not yet fully familiar with result interpretation, clinical implementation of commercially available lung cancer diagnostic biomarkers should not be pursued. We acknowledge that more work needs to be done to optimize implementation of novel biomarkers into routine clinical practice but disagree that no efforts should be made to harness the potential benefit of using biomarkers as complementary information to inform clinical decision-making while enhancing guideline-directed care. The current state of pulmonary nodule risk stratification and management is inadequate, as evidenced by a lack of standardized practice among physicians and poor adherence to published guidelines.2Farjah F. Monsell S.E. Gould M.K. et al.Association of the intensity of diagnostic evaluation with outcomes in incidentally detected lung nodules.JAMA Intern Med. 2021; 181: 480-489Crossref PubMed Scopus (21) Google Scholar, 3Tanner N.T. Porter A. Gould M.K. Li X.J. Vachani A. Silvestri G.A. Physician assessment of pretest probability of malignancy and adherence with guidelines for pulmonary nodule evaluation.Chest. 2017; 152: 263-270Abstract Full Text Full Text PDF PubMed Scopus (72) Google Scholar, 4Maiga A.W. Deppen S.A. Massion P.P. et al.Communication about the probability of cancer in indeterminate pulmonary nodules.JAMA Surg. 2018; 153: 353-357Crossref PubMed Scopus (8) Google Scholar, 5Wiener R.S. Gould M.K. Slatore C.G. Fincke B.G. Schwartz L.M. Woloshin S. Resource use and guideline concordance in evaluation of pulmonary nodules for cancer: too much and too little care.JAMA Intern Med. 2014; 174: 871-880Crossref PubMed Scopus (99) Google Scholar Moreover, patients often feel confused and anxious when cancer risk is not explicitly discussed.6Wiener R.S. Gould M.K. Woloshin S. Schwartz L.M. Clark J.A. What do you mean, a spot?: a qualitative analysis of patients' reactions to discussions with their physicians about pulmonary nodules.Chest. 2013; 143: 672-677Abstract Full Text Full Text PDF PubMed Scopus (114) Google Scholar Therefore, it is paramount for pulmonologists to embrace well-validated tools which provide much-needed supplemental information on nodule malignancy risk to guide clinical management decisions. In the current information age landscape in which we practice, patients are often a step ahead of us regarding internet searches for the most cutting-edge technology relevant to their medical conditions and expect us to be knowledgeable in and offer them all available resources when engaging in shared decision-making.7Berwick D.M. Diagnostic excellence through the lens of patient-centeredness.JAMA. 2021; 326: 2127-2128Crossref PubMed Scopus (12) Google Scholar Because liquid biomarkers are already commercially available for clinical use in the United States, we as a field must learn how to best implement these tests into our clinical practice even as we continue to conduct the large-scale clinical utility trials essential to advancing our knowledge of their effectiveness. As our colleagues have astutely pointed out, additional research, education, and training is required before physicians will broadly implement liquid biomarkers into their practice, but this does not mean that the tests themselves are not yet ready for clinical implementation. Multiple rigorous clinical validation and registry studies have demonstrated that liquid biomarkers provide a meaningful supplemental datapoint to physicians,8Silvestri G.A. Tanner N.T. Kearney P. et al.Assessment of plasma proteomics biomarker's ability to distinguish benign from malignant lung nodules: results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) trial.Chest. 2018; 154: 491-500Abstract Full Text Full Text PDF PubMed Scopus (107) Google Scholar,9Massion P.P. Healey G.F. Peek L.J. et al.Autoantibody signature enhances the positive predictive power of computed tomography and nodule-based risk models for detection of lung cancer.J Thorac Oncol. 2017; 12: 578-584Abstract Full Text Full Text PDF PubMed Google Scholar and additional prospective clinical studies are already underway. It is now up to us to determine how and in what clinical situations to use this information when we discuss next steps in management with patients. If we want to improve how we manage indeterminate pulmonary nodules, perhaps rather than returning to our "regularly scheduled programming," we should instead take inspiration from Albert Einstein, who reminds us that "insanity is doing the same thing over and over again and expecting different results." R. Y. K. is supported by a National Cancer Institute Career Development Award [Grant K08CA279881]. C. R. S. receives support from the US Department of Veterans Affairs BLR&D, Merit Review grant [Grant I01-BX005353].
No takes yet. Share an insight, caveat, or question.
Kim et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: